Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repaymentsWages, Salaries and Other
Ratios

Mangoceuticals (MGRX) Shares Outstanding (2022 - 2025)

Mangoceuticals' Shares Outstanding history spans 4 years, with the latest figure at $15.9 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 389.54% to $15.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.9 million, a 389.54% increase, with the full-year FY2025 number at $15.9 million, up 389.54% from a year prior.
  • Shares Outstanding hit $50.0 in Q4 2025 for Mangoceuticals, down from $13.9 million in the prior quarter.
  • Over the last five years, Shares Outstanding for MGRX hit a ceiling of $16.8 million in Q3 2023 and a floor of -$15.6 million in Q2 2023.
  • Historically, Shares Outstanding has averaged $3.0 million across 4 years, with a median of $980000.0 in 2024.
  • The widest YoY moves for Shares Outstanding: up 614.75% in 2025, down 99.94% in 2025.
  • Tracing MGRX's Shares Outstanding over 4 years: stood at $891000.0 in 2022, then skyrocketed by 60.27% to $1.4 million in 2023, then soared by 127.29% to $3.2 million in 2024, then skyrocketed by 389.54% to $15.9 million in 2025.
  • Business Quant data shows Shares Outstanding for MGRX at $15.9 million in Q4 2025, $13.9 million in Q3 2025, and $582.0 in Q2 2025.